Ranolazine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ranolazine: From Chronic Angina to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Ranolazine is currently used as a second-line agent for chronic angina, acting through inhibition of the late/persistent cardiac sodium current (I_NaL). The TxGNN model’s top-ranked prediction is Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this pairing currently has zero clinical trials and zero publications, and the model’s own rationale states there is no known mechanistic link between the two.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic angina (per literature reference PMID 41293236; not yet confirmed via an official EU/Taiwan regulatory label — see Data Gaps below) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
A formal, sourced description of ranolazine’s mechanism of action is not available in this evidence pack (original_moa: Data Gap). However, information embedded in the model’s own rationale fields indicates ranolazine works by inhibiting the late cardiac sodium current (I_NaL), which reduces intracellular sodium/calcium overload in ischemic myocardium — the pharmacological basis for its established antianginal effect.
NSIAD, by contrast, is caused by gain-of-function mutations in the vasopressin V2 receptor (AVPR2), a renal water-handling pathway that is mechanistically unrelated to cardiac sodium channel modulation. The evidence pack’s own repurposing rationale for this pairing is explicit: “NSIAD is caused by AVPR2 gain-of-function mutations, with no known overlap with ranolazine’s late cardiac sodium current inhibition mechanism; no reasonable biological connection.”
Given the complete absence of clinical trials, ICTRP registrations, or literature support, combined with this documented lack of mechanistic plausibility, the NSIAD prediction most likely reflects a knowledge-graph connectivity artifact rather than a genuine repurposing signal. Notably, of the 10 candidates in this evidence pack, headache disorder (rank 9) carries materially stronger support — three literature items, a plausible sodium-channel-related mechanism relevant to migraine, and evidence level L4 (decision stage S1, “Research Question”) — and may be a more productive direction for further review, even though it is not the top-ranked TxGNN score.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Ranolazine currently holds no EU marketing authorizations on record in this evidence pack (0 licenses; market status: Not Marketed).
Safety Considerations
Please refer to the SmPC for safety information.
Supplementary note: a real-world pharmacovigilance analysis of ranolazine using the FAERS database (PMID 41293236, 2025) is available in the literature associated with a different candidate indication (headache disorder) in this pack, and may be a useful starting point once formal label data (warnings/contraindications) is obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (NSIAD) has no supporting clinical or literature evidence, and its own documented mechanistic rationale confirms no plausible biological link to ranolazine’s sodium-channel-based mode of action. Ranolazine also currently has no EU marketing authorization, adding a regulatory barrier on top of the scientific one.
To proceed, the following is needed:
- TFDA label warnings/contraindications (Data Gap DG001, Blocking — required before any S1 safety review)
- Confirmed, sourced mechanism-of-action documentation (Data Gap DG002, High)
- If repurposing is still of interest, re-prioritize evaluation toward candidates with actual evidence, in particular headache disorder (L4, S1, three supporting literature items) rather than the top TxGNN-score pairing
- If NSIAD is to be pursued regardless, preclinical/mechanistic studies establishing a plausible pathway would be required before any clinical evidence search is warranted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.